tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Chen CH et al. Comparison of tuberculosis infection rates in a national database of renal transplant patients with data from a single center in Taiwan. 2014 Transplant. Proc. pmid:24656019
Hattori Y et al. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus. 2014 Transplant. Proc. pmid:24656015
Meiser BM and Reichart B New trends in clinical immunosuppression. 1994 Transplant. Proc. pmid:7527954
Nakajima K et al. Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. 1993 Transplant. Proc. pmid:7679821
Ohtsuka S et al. Hamster-to-rat xenotransplantation of whole pancreas by FK 506 combined with splenectomy. 1994 Transplant. Proc. pmid:7513473
Goto T et al. FK 506: historical perspectives. 1991 Transplant. Proc. pmid:1721254
Ciancio G et al. Current advantage of FK 506 in cadaveric kidney transplantation. 1996 Transplant. Proc. pmid:8623207
Furian L et al. Everolimus associated with low-dose calcineurin inhibitors, an option in kidney transplant recipients of very old donors. 2014 Transplant. Proc. pmid:25498057
Jain AB et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. 1990 Transplant. Proc. pmid:1689900
Fung JJ et al. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. 1990 Transplant. Proc. pmid:1689901
Bechstein WO et al. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. 2013 Jul-Aug Transplant. Proc. pmid:23953523
Van Buren D et al. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus). 1998 Transplant. Proc. pmid:9636566
Ichikura H et al. Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience. 2000 Transplant. Proc. pmid:11119911
Zhao YJ et al. Late, severe, noninfectious diarrhea after renal transplantation: high-risk factors, therapy, and prognosis. 2013 Jul-Aug Transplant. Proc. pmid:23953533
Pedroso JA et al. Elderly kidney transplant recipient with intermittent fever: a case report of leishmaniasis with acute kidney injury during liposomal amphotericin B therapy. 2014 Transplant. Proc. pmid:25242789
Jain A et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. 1998 Transplant. Proc. pmid:9636567
Manu M et al. Impact of tacrolimus on hyperlipidemia after renal transplantation: a Japanese single center experience. 2000 Transplant. Proc. pmid:11119912
Morales JM et al. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients. 2005 Transplant. Proc. pmid:16386523
Pascual J et al. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. 2005 Transplant. Proc. pmid:16386525
Lopes CT et al. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. 2008 Transplant. Proc. pmid:18455036
Mañez R et al. Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. 1993 Transplant. Proc. pmid:7680170
Woan MC et al. Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. 1993 Transplant. Proc. pmid:7680171
Müller MK et al. Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. 1991 Transplant. Proc. pmid:1721286
Francavilla A et al. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. 1991 Transplant. Proc. pmid:1721287
Carobbi A et al. Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. 1992 Transplant. Proc. pmid:1373543
Ketel BL et al. Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation. 1996 Transplant. Proc. pmid:8623453
Kyo M et al. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin. 1996 Transplant. Proc. pmid:8623457
Barreto P et al. Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Kidney Graft Recipients. 2016 Transplant. Proc. pmid:27742278
Bruce DS et al. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9636625
Moffatt SD and Metcalfe SM FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578271
Amada N et al. Deoxyspergualin prophylaxis with tacrolimus further improves long-term graft survival in living-related renal-transplant recipients transfused with donor-specific blood. 2005 Transplant. Proc. pmid:15848577
YaÄŸmurdur MC et al. Tacrolimus conversion in kidney transplant recipients: analysis of 107 patients. 2004 Jan-Feb Transplant. Proc. pmid:15013327
Kim SJ et al. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. 2009 Transplant. Proc. pmid:19545705
Sánchez-Lázaro IJ et al. Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation. 2010 Transplant. Proc. pmid:20970650
Hayashi S et al. Synergistic effect of donor pretreatment using FK 506 in hamster-to-rat cardiac xenotransplantation. 1994 Transplant. Proc. pmid:7518126
Woodle ES et al. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. 1993 Transplant. Proc. pmid:7682358
Senninger N et al. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. 1995 Transplant. Proc. pmid:7533364
Yagihashi A et al. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721318
Tanabe K et al. Synergistic effect of high-dose mizoribine and low-dose tacrolimus on renal allograft survival in nonhuman primates. 2002 Transplant. Proc. pmid:12176425
Ito Y et al. Inhibition of epithelial replacement by nonspecific immunosuppressants accelerates rat orthotopic tracheal allograft rejection. 2002 Transplant. Proc. pmid:12176430
Izuishi K et al. Effect of an immunosuppressive agent, tacroliums (FK-506), on the activities of cytochrome P-450-linked monooxygenase systems of rat liver microsomes. 2003 Transplant. Proc. pmid:12591538
Kindt MV et al. Tacrolimus toxicity in rhesus monkey: model for clinical side effects. 1999 Transplant. Proc. pmid:10616519
Gaston RS Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens. 1999 Transplant. Proc. pmid:10616556
Sugitani A et al. Long-term results of tacrolimus therapy for renal transplantation in patients with diabetic nephropathy in Japan. 2005 Transplant. Proc. pmid:15919459
Saito S et al. The pattern of rejection and susceptibility to different kinds of immunosuppression after combined liver, duodenum, and pancreas transplantation in swine--immunosuppressive drugs versus ex vivo immunomodulation of the allograft. 1995 Transplant. Proc. pmid:7533420
Tashiro H et al. Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. 1995 Transplant. Proc. pmid:7533421
Morel P et al. Liver retransplantation in adults: overall results and determinant factors affecting the outcome. 1991 Transplant. Proc. pmid:1721349
Cakir U et al. Role of Everolimus on Cardiac Functions in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28340820
Felser I et al. Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721350
Yoshimura N et al. Effect of local immunosuppressive therapy with FK 506 on renal allograft survival in the mongrel dog. 1998 Transplant. Proc. pmid:9838372
Bartlomiejczyk I et al. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods. 2006 Jan-Feb Transplant. Proc. pmid:16504673
Falkiewicz K et al. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation. 2006 Jan-Feb Transplant. Proc. pmid:16504680
Hernández D et al. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. 2003 Transplant. Proc. pmid:12962773
Pascual J et al. A low incidence of new-onset insulin-dependent diabetes mellitus using tacrolimus in kidney recipients in Europe. 2003 Transplant. Proc. pmid:12962785
Bonatti H et al. Liver transplantation for acute liver failure in children under 1 year of age. 1997 Feb-Mar Transplant. Proc. pmid:9123068
Cicalese L et al. Effect of FK506 on the mucosal perfusion of the rat intestinal allograft. 1996 Transplant. Proc. pmid:8907959
Craig AM et al. A cost-effectiveness analysis of tacrolimus versus cyclosporine microemulsion following kidney transplantation. 2002 Transplant. Proc. pmid:12176519
Rashid I et al. Medium-term outcome using sirolimus-tacrolimus combination in adult renal transplant recipients. 2002 Transplant. Proc. pmid:12176520
Oishi M et al. Successful swine small bowel transplantation using FK506: effect on endotoxin translocation. 1994 Transplant. Proc. pmid:7520629
Jiang H et al. FK 506 and deoxyspergualin: additive immunosuppressive effect on rat cardiac allograft rejection in vivo and mitogen-stimulated human lymphocyte responses in vitro. 1994 Transplant. Proc. pmid:7520631
Moutabarrik A et al. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. 1991 Transplant. Proc. pmid:1721382
Moutabarrik A et al. In vitro FK 506 kidney tubular cell toxicity. 1991 Transplant. Proc. pmid:1721383
Youbin Z et al. Tumor Necrosis Factor-α-Induced Protein 8-Like 2 Gene Overexpression Prolongs the Survival of Rat Allogeneic Heart Allografts. 2015 Transplant. Proc. pmid:26518962
Yamamoto T et al. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report. Transplant. Proc. pmid:28104125
Navia MA Rational design of new immunosuppressive drugs. 1999 Feb-Mar Transplant. Proc. pmid:10083489
Tsao CI et al. Unplanned readmission within 1 year after heart transplantation in Taiwan. 2010 Transplant. Proc. pmid:20430212
Gruessner AC et al. Solitary pancreas transplants: improving results and factors that influence outcome. 1997 Feb-Mar Transplant. Proc. pmid:9123468
Jonas S et al. Corticosteroid-free therapy after tacrolimus-based dual immunosuppression versus cyclosporine-based quadruple-induction therapy. 2001 Transplant. Proc. pmid:11377511
Boucher A et al. Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients. 2002 Transplant. Proc. pmid:12176582
Chang HR et al. Predictors of renal function improvement following tacrolimus conversion in cyclosporine-treated kidney transplant recipients. 2007 Transplant. Proc. pmid:18089339
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation in rats. 1991 Transplant. Proc. pmid:1721413
Tanabe K et al. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. 1996 Transplant. Proc. pmid:8658670
Lee KH et al. Distribution of Anti-ABO Immunoglobulin G Subclass and C1q Antibody in ABO-incompatible Kidney Transplantation. 2018 Transplant. Proc. pmid:29731066
Htun YY et al. CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients. 2018 Transplant. Proc. pmid:29731062
Wang W et al. Effect of rapamycin and FK506 on mesangial cell proliferation. 2001 Feb-Mar Transplant. Proc. pmid:11267180
Salazar A et al. Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: effect on renal function. 2001 Feb-Mar Transplant. Proc. pmid:11267181
Curtis JJ Posttransplant hypertension. 1998 Transplant. Proc. pmid:9723370
Li Y et al. Long-term comparison of rat model of chronic allograft rejection of orthotopic small bowel transplantation induced by cyclosporine versus tacrolimus. 2013 Transplant. Proc. pmid:23769050
Yoshimura R et al. Hepatocyte growth factor: a sensitive indicator for CsA-induced nephropathy. 1998 Transplant. Proc. pmid:9723373
Asensio M et al. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids. 2002 Transplant. Proc. pmid:12176650
Sindhi R et al. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants. 2002 Transplant. Proc. pmid:12176651
Kandaswamy R et al. Can we maintain immunosuppression avoiding nephrotoxic agents in pancreas transplantation? 2008 Transplant. Proc. pmid:18374118
Zajicek A et al. Thirteen years' experience in pediatric liver transplantation: differences between tacrolimus and cyclosporine. 2002 Transplant. Proc. pmid:12176653
Kanodia KV et al. Study of acute antibody-mediated rejection in renal allograft biopsies. 2008 Transplant. Proc. pmid:18555123
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
Lin CY et al. Effects of FK 506 on the biochemical markers in canine lung allograft rejection. 1991 Transplant. Proc. pmid:1721445
McMaster P and Buist L FK 506 in transplantation. 1993 Transplant. Proc. pmid:7689275
Jost U et al. FK 506 treatment of intractable rejection after liver transplantation. 1993 Transplant. Proc. pmid:7689276
Winkler M et al. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. 1993 Transplant. Proc. pmid:7689277
Langrehr JM et al. A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267404
Toki K et al. Histopathologic findings in routine biopsies of renal transplant allografts. 1999 Transplant. Proc. pmid:10500759
Baskiran A et al. Pregnancy After Liver Transplantation: Risks and Outcomes. 2017 Transplant. Proc. pmid:28923640
Silber RE et al. Comparison of the effect of FK 506 and alpha/beta-T-cell antibody R73 on transplant vascular sclerosis after heterotopic rat heart transplantation. 1998 Transplant. Proc. pmid:9636398
Barten MJ et al. Assessment of immunosuppression by lymphocyte functions in human blood. 2002 Transplant. Proc. pmid:12431640
Kacar S et al. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. 2010 Transplant. Proc. pmid:21094806
Keshavamurthy M et al. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral. 2001 Nov-Dec Transplant. Proc. pmid:11750338
Bing P et al. Comparison of expression of TGF-beta1, its receptors TGFbeta1R-I and TGFbeta1R-II in rat kidneys during chronic nephropathy induced by cyclosporine and tacrolimus. 2006 Transplant. Proc. pmid:16980036
Friemann S et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. 1998 Transplant. Proc. pmid:9636504
Fernando ON et al. Elective conversion of patients from cyclosporine to tacrolimus for hypertrichosis. 1998 Transplant. Proc. pmid:9636505
Nakamura A et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. 2014 Transplant. Proc. pmid:24656020